{"entity":{"id":"nct07595835","kind":"trial","name":"CT-guided Percutaneous Radionuclide Therapy With 32P Microparticles in Patients With Non-progressive Locally Advanced Pancreatic Cancer","aka":["PANCOSIL"],"tldr":"A phase 1/2 trial in pancreatic cancer, run by M.R. Meijerink, now recruiting.","summary":"CT-guided Percutaneous Radionuclide Therapy With 32P Microparticles in Patients With Non-progressive Locally Advanced Pancreatic Cancer is a phase 1/2, interventional study registered as NCT07595835 by M.R. Meijerink, with a registry enrolment figure of 20 participants, started 2023-06-04 and due to reach its primary completion in 2026-06-01. Interventions recorded: CT-guided percutaneous intratumoural implantation of the OncoSil™ device. Conditions listed: Pancreatic Cancer. Primary outcome: Safety defined as the rate of procedure- or device-related CTCAE grade ≥3 adverse events (AEs) within 90 days after implantion.. Pancreatic eligibility wording from the registry: \"* Locally advanced pancreatic cancer, defined by the DPCG consensus criteria as: arterial involvement \\>90 degrees or venous involvement \\>270 degrees\". Sites: Netherlands. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07595835","url":"https://clinicaltrials.gov/study/NCT07595835"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["locally-advanced-pdac"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07595835","phase":"1/2","setting":"Safety and Feasibility of CT-guided Percutaneous Radionuclide Therapy With 32P Microparticles in Patients With Non-progressive Locally Advanced Pancreatic Cancer (PANCOSIL): an Open-label, Single-arm Phase 1-2 Feasibility Study","sponsor":"M.R. Meijerink","participation":[{"nct":"NCT07595835","source":"https://clinicaltrials.gov/study/NCT07595835","fetchedAt":"2026-10-07T16:55:50.238Z","studySha256":"6cd6d5a40f3ffd1286eb2847abaf8ffccc3c32bbad9e186ff51e750876d5a8c6","overallStatus":"RECRUITING","lastUpdatePosted":"2026-05-22","leadSponsor":"M.R. Meijerink","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":20,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["Netherlands"]}],"started":"2023-06-04","startedType":"actual","enrolled":20,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07595835/","neighbours":{"cancer":[{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}